Data Supplement
- Supplemental Data -
Supplemental Materials and Methods
Supplemental Table 1 - Baseline demographics (safety analysis set).
Supplemental Table 2 - Mean concentration-time data for fevipiprant and its AG metabolite without and with probenecid.
Supplemental Table 3 - Adverse events by treatment (safety analysis set).